Doctors in Iran looked at the problem of osteoarthritis in the middle aged and elderly popoulation of Iranian hospitals. They noted limited success with traditional treatments and explored the safety of treatment with autologous bone marrow derived mesenchymal stem cells (MSCs) transplanted in patients with osteoarthritis of the knee, ankle, or hip.
Each patient received one mesenchymal stem cell injection. Patients were followed with clinical examinations, MRI and laboratory tests at 2, 6, 12, and 30 months post-transplantation.
The doctors observed no severe adverse events such as pulmonary embolism, death, or systemic complications. A limited number of patients had very minor localized adverse effects such as rash and erythema. There were no changes in liver function, hematology, or biochemistry analyses before and after cell therapy. There was no evidence of tumor or neoplastic changes in the patients during the 30-month follow-up period.
All patients exhibited therapeutic benefits such as:
- increased walking distance,
- decreased pain
- cartilage regrowth
The doctors concluded that stem cell injections into different osteoarthrts affected joints is safe and therapeutically beneficial.
Regeneration of knee cartilage is one of the most research subjects in recent medical literature, you can read more information on stem cell therapy for knee osteoarthritis and supportive research. Information on the treatment of varying degrees of hip osteoarthritis and stem cell therapy and supporting research.
Contact Ross Hauser MD about this article[contact-form-7 404 "Not Found"]
1. Emadedin M, Ghorbani Liastani M, Fazeli R, et al. Long-Term Follow-up of Intra-articular Injection of Autologous Mesenchymal Stem Cells in Patients with Knee, Ankle, or Hip Osteoarthritis. Arch Iran Med. 2015 Jun;18(6):336-44. doi: 015186/AIM.003.